2Merican I, Guan R, Amarapuka D, et al. Chronic hepatitis B virus infection in Asian countries [ J]. J Gastroenterol Hepatol, 2000, 15 (12) :1356 - 1361.
3Strader DB,Wright T,Thomas DL,et al.Diagnosis,management,and treatment of hepatitis C.Hepatology,2004,39:1147-1171.
4Seeger C,Mason WS.Hepatitis B virus biology.Microbiol Mol Biol Rev,2000,64:51-68.
5Scaglioni PP,Melegari M,Wands JR.Biologic properities of hepatitis B viral genomes with mutations in the precore promoter and precore open reading frame.Virology,1997,233:374-381.
6Lai CL,Dienstag J,Schiff E,et al.Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.Clin Infect Dis,2003,36:687-696.
7Hu KQ.Occult hepatitis B virus infection and its clinical implications.J Viral Hepat,2002,9:243-257.
8Janssen HL,van Zonneveld M,Senturk H,et al.Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B:a randomised trial.Lancet,2005,365:123-129.
9World Health Organization.Hepatitis B.World Health Organization Fact Sheet 204 dex.(Revised October 2000).WHO Web site.http://www.who.int/mediacentre/ factsheets/fs204/en/ in html.
10de FranchisR,Hadengue A,Lau G,et al.EASL International Consensus Conference on Hepatitis B.J Hepatol,2003,39 Suppll:S3-S25.
